If GRAIL’s Galleri Gets Approved, Rivals Must Beat Its Evidence
Wednesday’s FDA panel vote sets a clinical bar for Exact Sciences and Guardant
Beijing’s Vanke Backstop Meets Xi’s Washington Summit
Regulators urged banks not to tag overdue Vanke loans as NPLs as Xi arrives in Washington for talks with Trump.
WTI Just Hit $89. If Hormuz Reopens, Where Does Crude Land?
Iran’s seven-day offer and three hours of UNGA talks have cracked the war premium in oil. The real question is which sectors trade on that move first.
Pfizer’s Deal Caps What It Keeps From Raising Prices Abroad
A newly revealed clause changes the dividend math as Sept. 29 tariffs near.
JPMorgan Is Chasing India’s Deal Boom. Is JPM the Right Financial Stock to Own Now?
Dimon flew to Mumbai this week praising India’s growth while flagging its tax enforcement as a real problem for foreign investors.
Jensen Huang Is in the Room Where It Happens
Trump’s “AI Force” shifts Nvidia’s biggest policy risk in Washington.
Vertex Has a Nov. 30 FDA Date That Could Redefine It
Revenue is at $13 billion and growing. Povetacicept for kidney disease is the catalyst that decides whether VRTX is still a cystic fibrosis stock or something larger.
Nike Reports October 1 at a 12-Year Low. What Bulls Need to See.
With its S&P 100 exit effective Sept. 21, Q1 FY2027 is the first big test of Elliott Hill’s turnaround.
Salesforce Raised Its Revenue Target to $63 Billion. The Stock Is Still 34% Off Its High.
Dreamforce delivered hard numbers: Agentforce ARR up 240%, Q3 cRPO guidance at 14%, and a FY2030 target that more firms now believe.
Nucor’s Selloff Is About a Miss on the Street, Not a Miss in the Business
A roughly 6% drop after guidance that still shows accelerating earnings and record shipments is a cyclical investor’s moment to pay attention.